{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:16:23Z","timestamp":1795022183205,"version":"4.10.1"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s41669-026-00683-6","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:38:35Z","timestamp":1791668315000},"page":"967-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Economic and Humanistic Burden of Phenylketonuria Among Patients and Their Caregivers: A Systematic Literature Review"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6851-267X","authenticated-orcid":false,"given":"Judit","family":"J\u00f3zwiak-Hagym\u00e1sy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1961-9607","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Zelei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8606-5304","authenticated-orcid":false,"given":"Shailja","family":"Vaghela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8941-1382","authenticated-orcid":false,"given":"D\u00f3ra","family":"Mezei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4522-955X","authenticated-orcid":false,"given":"H\u00e9di","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9967-5824","authenticated-orcid":false,"given":"M\u00e1rk","family":"H\u00e1mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1599-3124","authenticated-orcid":false,"given":"Krist\u00f3f","family":"Gy\u00f6ngy\u00f6si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1934-2222","authenticated-orcid":false,"given":"Vanja","family":"Sikirica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6086-8389","authenticated-orcid":false,"given":"Sue","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"issue":"9750","key":"683_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau N, Van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(10)60961-0.","journal-title":"Lancet"},{"issue":"1","key":"683_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13023-021-01874-6","volume":"16","author":"PK Foreman","year":"2021","unstructured":"Foreman PK, Margulis AV, Alexander K, Shediac R, Calingaert B, Harding A, et al. Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta-analysis. Orphanet J Rare Dis. 2021;16(1):253. https:\/\/doi.org\/10.1186\/s13023-021-01874-6.","journal-title":"Orphanet J Rare Dis"},{"key":"683_CR3","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0009","author":"A L\u00fcders","year":"2021","unstructured":"L\u00fcders A, Blankenstein O, Brockow I, Ensenauer R, Lindner M, Schulze A, et al. Neonatal screening for congenital metabolic and endocrine disorders. Deutsches \u00c4rzteblatt Int. 2021. https:\/\/doi.org\/10.3238\/arztebl.m2021.0009.","journal-title":"Deutsches \u00c4rzteblatt Int"},{"issue":"1","key":"683_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijns7010015","volume":"7","author":"JG Loeber","year":"2010","unstructured":"Loeber JG, Platis D, Zetterstr\u00f6m RH, Almashanu S, Boemer F, Bonham JR, et al. Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments since 2010. IJNS. 2010;7(1):15. https:\/\/doi.org\/10.3390\/ijns7010015.","journal-title":"IJNS"},{"issue":"1","key":"683_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ Van Wegberg","year":"2017","unstructured":"Van Wegberg AMJ, MacDonald A, Ahring K, B\u00e9langer-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162. https:\/\/doi.org\/10.1186\/s13023-017-0685-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"683_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gim.2013.157","volume":"16","author":"J Vockley","year":"2014","unstructured":"Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188\u2013200. https:\/\/doi.org\/10.1038\/gim.2013.157.","journal-title":"Genet Med"},{"issue":"3","key":"683_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ymgme.2013.05.003","volume":"109","author":"I Eijgelshoven","year":"2013","unstructured":"Eijgelshoven I, Demirdas S, Smith TA, Van Loon JMT, Latour S, Bosch AM. The time consuming nature of phenylketonuria: a cross-sectional study investigating time burden and costs of phenylketonuria in the Netherlands. Mol Genet Metab. 2013;109(3):237\u201342. https:\/\/doi.org\/10.1016\/j.ymgme.2013.05.003.","journal-title":"Mol Genet Metab"},{"key":"683_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgmr.2016.08.008","volume":"9","author":"A MacDonald","year":"2016","unstructured":"MacDonald A, Smith TA, De Silva S, Alam V, Van Loon JMT. The personal burden for caregivers of children with phenylketonuria: a cross-sectional study investigating time burden and costs in the UK. Mol Genet Metab Rep. 2016;9:1\u20135. https:\/\/doi.org\/10.1016\/j.ymgmr.2016.08.008.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"683_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.70194","volume":"49","author":"N Longo","year":"2026","unstructured":"Longo N, Burton BK, Vaghela S, Mu F, Wang A, Smith J, et al. Disease burden and pharmacological treatment patterns in children and adults with phenylketonuria: a real\u2010world matched cohort study. J Inherit Metab Dis. 2026;49(3):e70194. https:\/\/doi.org\/10.1002\/jimd.70194.","journal-title":"J Inherit Metab Dis"},{"key":"683_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.100764","volume":"27","author":"F Trefz","year":"2021","unstructured":"Trefz F, Muntau AC, Schneider KM, Altevers J, Jacob C, Braun S, et al. Health economic burden of patients with phenylketonuria (PKU)\u2014a retrospective study of German health insurance claims data. Mol Genet Metab Rep. 2021;27:100764. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100764.","journal-title":"Mol Genet Metab Rep."},{"key":"683_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/9681740","author":"PM Luna","year":"2023","unstructured":"Luna PM, L\u00f3pez-Paz JF, Garc\u00eda M, Amayra I, Mart\u00ednez O, P\u00e9rez M, et al. Cognitive functioning in adults with phenylketonuria in a cohort of Spanish patients. Behav Neurol. 2023. https:\/\/doi.org\/10.1155\/2023\/9681740.","journal-title":"Behav Neurol"},{"issue":"1","key":"683_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymgme.2015.11.006","volume":"117","author":"F Manti","year":"2016","unstructured":"Manti F, Nardecchia F, Chiarotti F, Carducci C, Carducci C, Leuzzi V. Psychiatric disorders in adolescent and young adult patients with phenylketonuria. Mol Genet Metab. 2016;117(1):12\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2015.11.006.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"683_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.17712\/nsj.2015.4.20150319","volume":"20","author":"M Gunduz","year":"2015","unstructured":"Gunduz M, Arslan N, Unal O, Cakar S, Kuyum P, Bulbul SF. Depression and anxiety among parents of phenylketonuria children. NSJ. 2015;20(4):350\u20136. https:\/\/doi.org\/10.17712\/nsj.2015.4.20150319.","journal-title":"NSJ."},{"key":"683_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"3","key":"683_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/JBIES-22-00430","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth. 2023;21(3):494\u2013506. https:\/\/doi.org\/10.11124\/JBIES-22-00430.","journal-title":"JBI Evid Synth."},{"issue":"3","key":"683_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.11124\/JBIES-23-00268","volume":"22","author":"TH Barker","year":"2024","unstructured":"Barker TH, Habibi N, Aromataris E, Stone JC, Leonardi-Bee J, Sears K, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid Synth. 2024;22(3):378\u201388. https:\/\/doi.org\/10.11124\/JBIES-23-00268.","journal-title":"JBI Evid Synth"},{"key":"683_CR17","unstructured":"Study Quality Assessment Tools | NHLBI, NIH [Internet]. [cited 2025 Jun 27]. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"683_CR18","unstructured":"SIGN [Internet]. [cited 2025 Jun 27]. Checklists. Available from: https:\/\/testing36.scot.nhs.uk"},{"key":"683_CR19","unstructured":"Checklist_for_Cohort_Studies.docx [Internet]. [cited 2025 Jun 30]. https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fjbi.global%2Fsites%2Fdefault%2Ffiles%2F2021-10%2FChecklist_for_Cohort_Studies.docx&wdOrigin=BROWSELINK"},{"key":"683_CR20","unstructured":"Checklist_for_Prevalence_Studies.docx [Internet]. [cited 2025 Jun 30]. https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fjbi.global%2Fsites%2Fdefault%2Ffiles%2F2021-10%2FChecklist_for_Prevalence_Studies.docx&wdOrigin=BROWSELINK"},{"key":"683_CR21","doi-asserted-by":"publisher","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Database System Rev Implement Rep. 2019 Sep 23;Publish Ahead of Print. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","DOI":"10.11124\/JBISRIR-D-19-00099"},{"issue":"4","key":"683_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","volume":"16","author":"CC Adarkwah","year":"2016","unstructured":"Adarkwah CC, Van Gils PF, Hiligsmann M, Evers SMAA. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):513\u201323. https:\/\/doi.org\/10.1586\/14737167.2015.1103185.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"683_CR23","unstructured":"The Fed - Foreign Exchange Rates - G.5A Annual [Internet]. [cited 2025 Jul 4]. https:\/\/www.federalreserve.gov\/releases\/g5a\/current\/"},{"issue":"2","key":"683_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/00125817-200203000-00006","volume":"4","author":"AS Brown","year":"2002","unstructured":"Brown AS, Fernhoff PM, Waisbren SE, Frazier DM, Singh R, Rohr F, et al. Barriers to successful dietary control among pregnant women with phenylketonuria. Genet Med. 2002;4(2):84\u20139. https:\/\/doi.org\/10.1097\/00125817-200203000-00006.","journal-title":"Genet Med"},{"issue":"4","key":"683_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/BF01797933","volume":"14","author":"J-L Dhondt","year":"1991","unstructured":"Dhondt J-L, Farriaux J-P, Sailly J-C, Lebrun T. Economic evaluation of cost\u2010benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism. J Inherit Metab Dis. 1991;14(4):633\u20139. https:\/\/doi.org\/10.1007\/BF01797933.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"683_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1053\/jpdn.2003.36","volume":"18","author":"CY Read","year":"2003","unstructured":"Read CY. The demands of biochemical genetic disorders: a survey of mothers of children with mitochondrial disease or phenylketonuria. J Pediatr Nurs. 2003;18(3):181\u20136. https:\/\/doi.org\/10.1053\/jpdn.2003.36.","journal-title":"J Pediatr Nurs"},{"key":"683_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100523","volume":"21","author":"AM Rose","year":"2019","unstructured":"Rose AM, Grosse SD, Garcia SP, Bach J, Kleyn M, Simon NJE, et al. The financial and time burden associated with phenylketonuria treatment in the United States. Mol Genet Metab Rep. 2019;21:100523. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100523.","journal-title":"Mol Genet Metab Rep."},{"issue":"3","key":"683_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10545-016-9995-0","volume":"40","author":"L Wang","year":"2017","unstructured":"Wang L, Zou H, Ye F, Wang K, Li X, Chen Z, et al. Household financial burden of phenylketonuria and its impact on treatment in China: a cross-sectional study. J Inher Metab Disea. 2017;40(3):369\u201376. https:\/\/doi.org\/10.1007\/s10545-016-9995-0.","journal-title":"J Inher Metab Disea."},{"issue":"1","key":"683_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12913-020-5054-5","volume":"20","author":"M Sellos-Moura","year":"2020","unstructured":"Sellos-Moura M, Glavin F, Lapidus D, Evans K, Lew CR, Irwin DE. Prevalence, characteristics, and costs of diagnosed homocystinuria, elevated homocysteine, and phenylketonuria in the United States: a retrospective claims-based comparison. BMC Health Serv Res. 2020;20(1):183. https:\/\/doi.org\/10.1186\/s12913-020-5054-5.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"683_CR30","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.jval.2021.11.272","volume":"25","author":"P Okhuoya","year":"2022","unstructured":"Okhuoya P, Altevers J, Arnoux J, Bou\u00e9e S, Charri\u00e8re S, Jacob C, et al. POSA129 health economic impact of phenylketonuria: a retrospective claims database study in France. Value Health. 2022;25(1):S59. https:\/\/doi.org\/10.1016\/j.jval.2021.11.272.","journal-title":"Value Health."},{"issue":"4","key":"683_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40261-019-00760-1","volume":"39","author":"J Darb\u00e0","year":"2019","unstructured":"Darb\u00e0 J, Ascanio M. Admissions and cost of hospitalisation of phenylketonuria: Spanish claims database analysis. Clin Drug Investig. 2019;39(4):379\u201384. https:\/\/doi.org\/10.1007\/s40261-019-00760-1.","journal-title":"Clin Drug Investig"},{"issue":"10","key":"683_CR32","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/13696998.2019.1636381","volume":"22","author":"J Darb\u00e0","year":"2019","unstructured":"Darb\u00e0 J. Characteristics, comorbidities, and use of healthcare resources of patients with phenylketonuria: a population-based study. J Med Econ. 2019;22(10):1025\u20139. https:\/\/doi.org\/10.1080\/13696998.2019.1636381.","journal-title":"J Med Econ"},{"issue":"1","key":"683_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1046\/j.1365-2788.1999.43120176.x","volume":"43","author":"MCJ Brown","year":"1999","unstructured":"Brown MCJ, Guest JF. Economic impact of feeding a phenylalanine\u2010restricted diet to adults with previously untreated phenylketonuria. J Intellect Disabil Res. 1999;43(1):30\u20137. https:\/\/doi.org\/10.1046\/j.1365-2788.1999.43120176.x.","journal-title":"J Intellect Disabil Res"},{"issue":"11","key":"683_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/nu13113977","volume":"13","author":"G Wood","year":"2021","unstructured":"Wood G, Pinto A, Evans S, Daly A, Adams S, Costelloe S, et al. Special low protein foods prescribed in England for PKU patients: an analysis of prescribing patterns and cost. Nutrients. 2021;13(11):3977. https:\/\/doi.org\/10.3390\/nu13113977.","journal-title":"Nutrients"},{"issue":"3","key":"683_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ymgme.2018.09.006","volume":"125","author":"BK Burton","year":"2018","unstructured":"Burton BK, Jones KB, Cederbaum S, Rohr F, Waisbren S, Irwin DE, et al. Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria. Mol Genet Metab. 2018;125(3):228\u201334. https:\/\/doi.org\/10.1016\/j.ymgme.2018.09.006.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"683_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107625","volume":"139","author":"S Charri\u00e8re","year":"2023","unstructured":"Charri\u00e8re S, Maillot F, Bou\u00e9e S, Douillard C, Jacob C, Schneider KM, et al. Health status and comorbidities of adult patients with phenylketonuria (PKU) in France with a focus on early-diagnosed patients \u2013 a nationwide study of health insurance claims data. Mol Genet Metab. 2023;139(3):107625. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107625.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"683_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1165-7","volume":"14","author":"R Min","year":"2019","unstructured":"Min R, Zhang X, Fang P, Wang B, Wang H. Health service security of patients with 8 certain rare diseases: evidence from China\u2019s national system for health service utilization of patients with healthcare insurance. Orphanet J Rare Dis. 2019;14(1):204. https:\/\/doi.org\/10.1186\/s13023-019-1165-7.","journal-title":"Orphanet J Rare Dis"},{"key":"683_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2024.101134","volume":"41","author":"JB Arnoux","year":"2024","unstructured":"Arnoux JB, Douillard C, Maillot F, Bou\u00e9e S, Jacob C, Schneider KM, et al. Health economic impact of patients with phenylketonuria (PKU) in France\u2014a nationwide study of health insurance claims data. Mol Genet Metab Rep. 2024;41:101134. https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101134.","journal-title":"Mol Genet Metab Rep."},{"issue":"1","key":"683_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-026-14801-x","volume":"26","author":"M Ye\u015fildal","year":"2026","unstructured":"Ye\u015fildal M, Eri\u015fen MA, E\u015fgi M. Out-of-pocket expenditures, accessibility, and affordability of low-protein nutrition in rare metabolic disorders in T\u00fcrkiye. BMC Health Serv Res. 2026;26(1):1005. https:\/\/doi.org\/10.1186\/s12913-026-14801-x.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"683_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ymgme.2011.12.004","volume":"105","author":"A Belanger-Quintana","year":"2012","unstructured":"Belanger-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, Motzfeldt K, et al. Diet in phenylketonuria: a snapshot of special dietary costs and reimbursement systems in 10 international centers. Mol Genet Metab. 2012;105(3):390\u20134. https:\/\/doi.org\/10.1016\/j.ymgme.2011.12.004.","journal-title":"Mol Genet Metab"},{"key":"683_CR41","unstructured":"Desancic S, Stoimenova A, Savova A, Manova M, Petkova V, Petrova G. Pharmacoeconomics of rare diseases therapy - An example of phenylketonuria. Acta Medica Bulgarica. 2011 Jan;XXXVIII(1):84\u20139."},{"issue":"1","key":"683_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/ejcn.2017.102","volume":"72","author":"T Ml\u010doch","year":"2018","unstructured":"Ml\u010doch T, Puda R, Je\u0161ina P, Lhot\u00e1kov\u00e1 M, \u0160t\u011brbov\u00e1 \u0160, Dole\u017eal T. Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases. Eur J Clin Nutr. 2018;72(1):87\u201392. https:\/\/doi.org\/10.1038\/ejcn.2017.102.","journal-title":"Eur J Clin Nutr"},{"key":"683_CR43","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-5276.18.05126-5","author":"L Borghi","year":"2021","unstructured":"Borghi L, Salvatici E, Banderali G, Riva E, Giovannini M, Vegni E. Psychological wellbeing in parents of children with phenylketonuria and association with treatment adherence. Minerva Pediatr. 2021. https:\/\/doi.org\/10.23736\/S2724-5276.18.05126-5.","journal-title":"Minerva Pediatr"},{"issue":"2","key":"683_CR44","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jpepsy\/jsaa100","volume":"46","author":"AE Mitchell","year":"2021","unstructured":"Mitchell AE, Morawska A, Kirby G, McGill J, Coman D, Inwood A. Triple P for parents of children with phenylketonuria: a nonrandomized trial. J Pediatr Psychol. 2021;46(2):208\u201318. https:\/\/doi.org\/10.1093\/jpepsy\/jsaa100.","journal-title":"J Pediatr Psychol"},{"issue":"1","key":"683_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/cch.12727","volume":"46","author":"A Morawska","year":"2020","unstructured":"Morawska A, Mitchell AE, Etel E, Kirby G, McGill J, Coman D, et al. Psychosocial functioning in children with phenylketonuria: relationships between quality of life and parenting indicators. Child. 2020;46(1):56\u201365. https:\/\/doi.org\/10.1111\/cch.12727.","journal-title":"Child"},{"issue":"1567","key":"683_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.26635\/6965.5949","volume":"135","author":"N Randell","year":"2022","unstructured":"Randell N, Barker-Collo S, Murrell K, Wilson C. Outcomes in mild hyperphenylalaninemia: a comparison with PKU and healthy controls across cognition, behaviour, and quality of life. N Z Med J. 2022;135(1567):31\u201342. https:\/\/doi.org\/10.26635\/6965.5949.","journal-title":"N Z Med J"},{"issue":"1","key":"683_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/jmd2.12202","volume":"59","author":"AG Thiele","year":"2021","unstructured":"Thiele AG, Spie\u00df N, Ascherl R, Arelin M, Rohde C, Kiess W, et al. Psychological well\u2010being of early and continuously treated phenylketonuria patients. JIMD Rep. 2021;59(1):69\u201380. https:\/\/doi.org\/10.1002\/jmd2.12202.","journal-title":"JIMD Rep"},{"issue":"3","key":"683_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-025-06048-1","volume":"184","author":"A Mete Ye\u015fil","year":"2025","unstructured":"Mete Ye\u015fil A, Akar HT, Y\u0131ld\u0131z Y, Sivri S, \u00d6zmert EN. Assessing sleep habits in school-aged children with phenylketonuria: a comparative study. Eur J Pediatr. 2025;184(3):225. https:\/\/doi.org\/10.1007\/s00431-025-06048-1.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"683_CR49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41687-019-0093-6","volume":"3","author":"NJ Simon","year":"2019","unstructured":"Simon NJ, Richardson J, Ahmad A, Rose A, Wittenberg E, D\u2019Cruz B, et al. Health utilities and parental quality of life effects for three rare conditions tested in newborns. J Patient Rep Outcomes. 2019;3(1):4. https:\/\/doi.org\/10.1186\/s41687-019-0093-6.","journal-title":"J Patient Rep Outcomes."},{"issue":"8","key":"683_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.rceng.2025.502356","volume":"225","author":"MA Mart\u00ednez Olmos","year":"2025","unstructured":"Mart\u00ednez Olmos MA, Venegas Moreno E, Morales Conejo M, Ceberio Hualde L, P\u00e9rez B, Forga MDT, et al. Clinical characteristics and management of Spanish adult patients with phenylketonuria. Revista Cl\u00ednica Espa\u00f1ola (English Edition). 2025;225(8):502356. https:\/\/doi.org\/10.1016\/j.rceng.2025.502356.","journal-title":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)"},{"issue":"1","key":"683_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0294-x","volume":"10","author":"AM Bosch","year":"2015","unstructured":"Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, et al. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet J Rare Dis. 2015;10(1):80. https:\/\/doi.org\/10.1186\/s13023-015-0294-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"683_CR52","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/jimd.12301","volume":"44","author":"F B\u00f6sch","year":"2021","unstructured":"B\u00f6sch F, Landolt MA, Baumgartner MR, Zeltner N, K\u00f6lker S, Gleich F, et al. Health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism: analysis of an international data set. J Inher Metab Disea. 2021;44(1):215\u201325. https:\/\/doi.org\/10.1002\/jimd.12301.","journal-title":"J Inher Metab Disea."},{"issue":"12","key":"683_CR53","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3390\/nu10121944","volume":"10","author":"H Demmelmair","year":"2018","unstructured":"Demmelmair H, MacDonald A, Kotzaeridou U, Burgard P, Gonzalez-Lamuno D, Verduci E, et al. Determinants of plasma docosahexaenoic acid levels and their relationship to neurological and cognitive functions in PKU patients: a double blind randomized supplementation study. Nutrients. 2018;10(12):1944. https:\/\/doi.org\/10.3390\/nu10121944.","journal-title":"Nutrients"},{"key":"683_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2023.113526","volume":"260","author":"ML Grant","year":"2023","unstructured":"Grant ML, Jurecki ER, McCandless SE, Stahl SM, Bilder DA, Sanchez-Valle A, et al. Neuropsychiatric function improvement in pediatric patients with phenylketonuria. J Pediatr. 2023;260:113526. https:\/\/doi.org\/10.1016\/j.jpeds.2023.113526.","journal-title":"J Pediatr"},{"issue":"3","key":"683_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107701","volume":"140","author":"LEF Janssen","year":"2023","unstructured":"Janssen LEF, Cassiman D, Brouwers MCGJ. Quality of life of adult patients with hereditary fructose intolerance. Mol Genet Metab. 2023;140(3):107701. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107701.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"683_CR56","doi-asserted-by":"publisher","first-page":"e1881","DOI":"10.1542\/peds.2012-3291","volume":"131","author":"S Keil","year":"2013","unstructured":"Keil S, Anjema K, Van Spronsen FJ, Lambruschini N, Burlina A, B\u00e9langer-Quintana A, et al. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study. Pediatrics. 2013;131(6):e1881\u20138. https:\/\/doi.org\/10.1542\/peds.2012-3291.","journal-title":"Pediatrics"},{"issue":"1","key":"683_CR57","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13023-023-02917-w","volume":"18","author":"S Maissen-Abgottspon","year":"2023","unstructured":"Maissen-Abgottspon S, Muri R, Hochuli M, Reismann P, Barta AG, Alptekin IM, et al. Health-related quality of life in a European sample of adults with early-treated classical PKU. Orphanet J Rare Dis. 2023;18(1):300. https:\/\/doi.org\/10.1186\/s13023-023-02917-w.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"683_CR58","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/jimd.12528","volume":"45","author":"K Van Vliet","year":"2022","unstructured":"Van Vliet K, Van Ginkel WG, Jahja R, Daly A, MacDonald A, Santra S, et al. Neurocognitive outcome and mental health in children with tyrosinemia type 1 and phenylketonuria: a comparison between two genetic disorders affecting the same metabolic pathway. J Inherit Metab Dis. 2022;45(5):952\u201362. https:\/\/doi.org\/10.1002\/jimd.12528.","journal-title":"J Inherit Metab Dis"},{"key":"683_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.100589","volume":"23","author":"AG Barta","year":"2020","unstructured":"Barta AG, Sum\u00e1nszki C, Turgonyi Z, Kiss E, Simon E, Serf\u0151z\u0151 C, et al. Health Related Quality of Life assessment among early-treated Hungarian adult PKU patients using the PKU-QOL adult questionnaire. Mol Genet Metab Rep. 2020;23:100589. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100589.","journal-title":"Mol Genet Metab Rep."},{"key":"683_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.100823","volume":"29","author":"D Becsei","year":"2021","unstructured":"Becsei D, Hiripi R, Kiss E, Szatm\u00e1ri I, Arat\u00f3 A, Reusz G, et al. Quality of life in children living with PKU\u2014a single-center, cross-sectional, observational study from Hungary. Mol Genet Metab Rep. 2021;29:100823. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100823.","journal-title":"Mol Genet Metab Rep."},{"key":"683_CR61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ymgmr.2017.12.003","volume":"14","author":"B Didycz","year":"2018","unstructured":"Didycz B, Bik-Multanowski M. Blood phenylalanine instability strongly correlates with anxiety in phenylketonuria. Mol Genet Metab Rep. 2018;14:80\u20132. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.12.003.","journal-title":"Mol Genet Metab Rep"},{"issue":"12","key":"683_CR62","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/nu11122857","volume":"11","author":"S Evans","year":"2019","unstructured":"Evans S, Daly A, Wildgoose J, Cochrane B, Ashmore C, Kearney S, et al. Mealtime anxiety and coping behaviour in parents and children during weaning in PKU: a case-control study. Nutrients. 2019;11(12):2857. https:\/\/doi.org\/10.3390\/nu11122857.","journal-title":"Nutrients"},{"issue":"6","key":"683_CR63","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/apa.13799","volume":"106","author":"R Feldmann","year":"2017","unstructured":"Feldmann R, Wolfgart E, Weglage J, Rutsch F. Sapropterin treatment does not enhance the health\u2010related quality of life of patients with phenylketonuria and their parents. Acta Paediatr. 2017;106(6):953\u20139. https:\/\/doi.org\/10.1111\/apa.13799.","journal-title":"Acta Paediatr"},{"issue":"16","key":"683_CR64","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.3390\/nu15163603","volume":"15","author":"MI Gama","year":"2023","unstructured":"Gama MI, Daly A, Ashmore C, Evans S, Moreira-Ros\u00e1rio A, Rocha JC, et al. Impact on diet quality and burden of care in sapropterin dihydrochloride use in children with phenylketonuria: a 6 month follow-up report. Nutrients. 2023;15(16):3603. https:\/\/doi.org\/10.3390\/nu15163603.","journal-title":"Nutrients"},{"issue":"1","key":"683_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-218","volume":"11","author":"TD Douglas","year":"2013","unstructured":"Douglas TD, Ramakrishnan U, Kable JA, Singh RH. Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride. Health Qual Life Outcomes. 2013;11(1):218. https:\/\/doi.org\/10.1186\/1477-7525-11-218.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"683_CR66","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/nu18030446","volume":"18","author":"O Yilmaz Nas","year":"2026","unstructured":"Yilmaz Nas O, Ashmore C, Gama MI, Daly A, Evans S, Pinto A, et al. Two-year outcomes of sapropterin treatment in children with phenylketonuria: a longitudinal observational study of metabolic, dietary, and psychosocial effects. Nutrients. 2026;18(3):446. https:\/\/doi.org\/10.3390\/nu18030446.","journal-title":"Nutrients"},{"issue":"1","key":"683_CR67","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1186\/1471-2458-14-1243","volume":"14","author":"C Cazzorla","year":"2014","unstructured":"Cazzorla C, Cegolon L, Burlina AP, Celato A, Massa P, Giordano L, et al. Quality of life (QoL) assessment in a cohort of patients with phenylketonuria. BMC Public Health. 2014;14(1):1243. https:\/\/doi.org\/10.1186\/1471-2458-14-1243.","journal-title":"BMC Public Health"},{"key":"683_CR68","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.ymgme.2013.09.015","volume":"110","author":"S Demirdas","year":"2013","unstructured":"Demirdas S, Maurice-Stam H, Boelen CCA, Hofstede FC, Janssen MCH, Langendonk JG, et al. Evaluation of quality of life in PKU before and after introducing tetrahydrobiopterin (BH4); a prospective multi-center cohort study. Mol Genet Metab. 2013;110:S49-56. https:\/\/doi.org\/10.1016\/j.ymgme.2013.09.015.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"683_CR69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ymgme.2018.07.002","volume":"125","author":"SCJ Huijbregts","year":"2018","unstructured":"Huijbregts SCJ, Bosch AM, Simons QA, Jahja R, Brouwers MCGJ, De Sonneville LMJ, et al. The impact of metabolic control and tetrahydrobiopterin treatment on health related quality of life of patients with early-treated phenylketonuria: a PKU-COBESO study. Mol Genet Metab. 2018;125(1\u20132):96\u2013103. https:\/\/doi.org\/10.1016\/j.ymgme.2018.07.002.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"683_CR70","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10545-012-9458-1","volume":"35","author":"B Ziesch","year":"2012","unstructured":"Ziesch B, Weigel J, Thiele A, M\u00fctze U, Rohde C, Ceglarek U, et al. Tetrahydrobiopterin (BH4) in PKU: effect on dietary treatment, metabolic control, and quality of life. J Inher Metab Disea. 2012;35(6):983\u201392. https:\/\/doi.org\/10.1007\/s10545-012-9458-1.","journal-title":"J Inher Metab Disea."},{"issue":"6","key":"683_CR71","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/jimd.12413","volume":"44","author":"L Aitkenhead","year":"2021","unstructured":"Aitkenhead L, Krishna G, Ellerton C, Moinuddin M, Matcham J, Shiel L, et al. Long-term cognitive and psychosocial outcomes in adults with phenylketonuria. J Inher Metab Disea. 2021;44(6):1353\u201368. https:\/\/doi.org\/10.1002\/jimd.12413.","journal-title":"J Inher Metab Disea."},{"issue":"S2","key":"683_CR72","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10545-008-0978-7","volume":"31","author":"M Bik\u2010Multanowski","year":"2008","unstructured":"Bik\u2010Multanowski M, Didycz B, Mozrzymas R, Nowacka M, Kaluzny L, Cichy W, et al. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J Inherit Metab Dis. 2008;31(S2):415\u20138. https:\/\/doi.org\/10.1007\/s10545-008-0978-7.","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"683_CR73","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1651-2227.2011.02227.x","volume":"100","author":"G Cotugno","year":"2011","unstructured":"Cotugno G, Nicol\u00f2 R, Cappelletti S, Goffredo B, Dionisi Vici C, Di Ciommo V. Adherence to diet and quality of life in patients with phenylketonuria. Acta Paediatr. 2011;100(8):1144\u20139. https:\/\/doi.org\/10.1111\/j.1651-2227.2011.02227.x.","journal-title":"Acta Paediatr"},{"key":"683_CR74","unstructured":"Rutsch F, Sazova O, Warrak S, Gu K, Kucuksayrac E, Muntau AC. OPAL: a multicenter, observational study to evaluate the real-world outcomes of pegvaliase in adults with phenylketonuria. In. Jerusalem, Israel; 2023."},{"key":"683_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2026.101323","volume":"47","author":"C Cazzorla","year":"2026","unstructured":"Cazzorla C, Gaiga G, Carretta J, Gragnaniello V, Loro C, Gueraldi D, et al. Quality of life after diet liberalization in individuals with phenylketonuria treated with pegvaliase. Mol Genet Metab Rep. 2026;47:101323. https:\/\/doi.org\/10.1016\/j.ymgmr.2026.101323.","journal-title":"Mol Genet Metab Rep."},{"issue":"1","key":"683_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108151","volume":"142","author":"I Scala","year":"2024","unstructured":"Scala I, Brodosi L, Gueraldi D, Manti F, Rovelli V, Zuvadelli J, et al. Pegvaliase therapy for phenylketonuria: real-world case series and clinical insights. Mol Genet Metab. 2024;142(1):108151. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108151.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"683_CR77","doi-asserted-by":"publisher","first-page":"030006052211255","DOI":"10.1177\/03000605221125524","volume":"50","author":"G Bensi","year":"2022","unstructured":"Bensi G, Carbone MT, Schiaffino MC, Parolisi S, Pozzoli A, Biasucci G. Quality of life aspects of a low protein diet using GMP in patients with phenylketonuria. J Int Med Res. 2022;50(9):03000605221125524. https:\/\/doi.org\/10.1177\/03000605221125524.","journal-title":"J Int Med Res"},{"issue":"4","key":"683_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108607","volume":"143","author":"A Pinto","year":"2024","unstructured":"Pinto A, Daly A, Newby C, Robotham A, Heales S, Eaton S, et al. The effects of casein glycomacropeptide on general health status in children with PKU: a randomized crossover trial. Mol Genet Metab. 2024;143(4):108607. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108607.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"683_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/nu12072078","volume":"12","author":"AP Burlina","year":"2020","unstructured":"Burlina AP, Cazzorla C, Massa P, Loro C, Gueraldi D, Burlina AB. The impact of a slow-release large neutral amino acids supplement on treatment adherence in adult patients with phenylketonuria. Nutrients. 2020;12(7):2078. https:\/\/doi.org\/10.3390\/nu12072078.","journal-title":"Nutrients"},{"issue":"9","key":"683_CR80","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/j.1651-2227.2005.tb02078.x","volume":"94","author":"HS Kalkano\u011flu","year":"2005","unstructured":"Kalkano\u011flu HS, Ahring KK, Sertkaya D, Birk M\u00f8ller L, Romstad A, Mikkelsen I, et al. Behavioural effects of phenylalanine\u2010free amino acid tablet supplementation in intellectually disabled adults with untreated phenylketonuria. Acta Paediatr. 2005;94(9):1218\u201322. https:\/\/doi.org\/10.1111\/j.1651-2227.2005.tb02078.x.","journal-title":"Acta Paediatr"},{"issue":"1","key":"683_CR81","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymgme.2012.02.008","volume":"106","author":"C Cazzorla","year":"2012","unstructured":"Cazzorla C, Del Rizzo M, Burgard P, Zanco C, Bordugo A, Burlina AB, et al. Application of the WHOQOL-100 for the assessment of quality of life of adult patients with inherited metabolic diseases. Mol Genet Metab. 2012;106(1):25\u201330. https:\/\/doi.org\/10.1016\/j.ymgme.2012.02.008.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"683_CR82","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1007\/s11136-024-03775-0","volume":"33","author":"K Konomura","year":"2024","unstructured":"Konomura K, Numakura C, Nakamura-Utsunomiya A, Hoshino E, Tajima G, Kobayashi H, et al. Health-related quality of life and caregiver burden of pediatric patients with inborn errors of metabolism in Japan using EQ-5D-Y, PedsQL, and J-ZBI. Qual Life Res. 2024;33(12):3323\u201333. https:\/\/doi.org\/10.1007\/s11136-024-03775-0.","journal-title":"Qual Life Res"},{"issue":"11","key":"683_CR83","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1111\/imj.70198","volume":"55","author":"A Cavanagh","year":"2025","unstructured":"Cavanagh A, Adhikary S, Denny S. Psychosocial well\u2010being of adolescents and young adults living with chronic illness. Intern Med J. 2025;55(11):1814\u201323. https:\/\/doi.org\/10.1111\/imj.70198.","journal-title":"Intern Med J"},{"issue":"6","key":"683_CR84","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s10545-009-1253-2","volume":"32","author":"AM Bosch","year":"2009","unstructured":"Bosch AM, Maurice\u2010Stam H, Wijburg FA, Grootenhuis MA. Remarkable differences: the course of life of young adults with galactosaemia and PKU. J Inherit Metab Dis. 2009;32(6):706\u201312. https:\/\/doi.org\/10.1007\/s10545-009-1253-2.","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"683_CR85","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/BF01972893","volume":"153","author":"MMT Hendrikx","year":"1994","unstructured":"Hendrikx MMT, Van Der Schot LWA, Slijper FME, Huisman J, Kalverboer AF. Phenylketonuria and some aspects of emotional development. Eur J Pediatr. 1994;153(11):832\u20135. https:\/\/doi.org\/10.1007\/BF01972893.","journal-title":"Eur J Pediatr"},{"issue":"12","key":"683_CR86","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.2337\/diacare.16.12.1572","volume":"16","author":"PJ St James","year":"1993","unstructured":"St James PJ, Younger MD, Hamilton BD, Waisbren SE. Unplanned pregnancies in young women with diabetes: an analysis of psychosocial factors. Diabetes Care. 1993;16(12):1572\u20138. https:\/\/doi.org\/10.2337\/diacare.16.12.1572.","journal-title":"Diabetes Care"},{"issue":"5","key":"683_CR87","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1023\/A:1005664231017","volume":"23","author":"J Weglage","year":"2000","unstructured":"Weglage J, Grenzebach M, Pietsch M, Feldmann R, Linnenbank R, Denecke J, et al. Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls. J Inher Metab Disea. 2000;23(5):487\u201396. https:\/\/doi.org\/10.1023\/A:1005664231017.","journal-title":"J Inher Metab Disea."},{"key":"683_CR88","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.clnesp.2018.06.005","volume":"27","author":"IM Alptekin","year":"2018","unstructured":"Alptekin IM, Koc N, Gunduz M, Cakiroglu FP. The impact of phenylketonuria on PKU patients\u2019 quality of life: using of the phenylketonuria-quality of life (PKU-QOL) questionnaires. Clin Nutr ESPEN. 2018;27:79\u201385. https:\/\/doi.org\/10.1016\/j.clnesp.2018.06.005.","journal-title":"Clin Nutr ESPEN"},{"issue":"4","key":"683_CR89","doi-asserted-by":"publisher","first-page":"232640981666937","DOI":"10.1177\/2326409816669373","volume":"29","author":"ED Bacci","year":"2016","unstructured":"Bacci ED, Wyrwich KW, Gries KS, Chen Y, Jain R, Konkol L, et al. An adaptation of the profile of mood states for use in adults with phenylketonuria. J Inborn Errors Metab Screen. 2016;29(4):232640981666937. https:\/\/doi.org\/10.1177\/2326409816669373.","journal-title":"J Inborn Errors Metab Screen."},{"issue":"11","key":"683_CR90","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1515\/jpem-2019-0253","volume":"32","author":"K Iakovou","year":"2019","unstructured":"Iakovou K, Schulpis K. Phenylketonuric patients represent their disease. J Pediatr Endocrinol Metab. 2019;32(11):1217\u201320. https:\/\/doi.org\/10.1515\/jpem-2019-0253.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"683_CR91","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s12325-021-01986-2","volume":"39","author":"J Quinn","year":"2022","unstructured":"Quinn J, Georgiadis A, Lewis HB, Jurecki E. Measuring burden of illness in phenylketonuria (PKU): development of the PKU symptom severity and impacts scale as a robust patient-reported outcome. Adv Ther. 2022;39(2):971\u201391. https:\/\/doi.org\/10.1007\/s12325-021-01986-2.","journal-title":"Adv Ther"},{"issue":"6","key":"683_CR92","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/03007995.2024.2337662","volume":"40","author":"V Rovelli","year":"2024","unstructured":"Rovelli V, Dicintio A, Cazzorla C. Unmet needs in phenylketonuria: an exploratory Italian survey among patients and caregivers. Curr Med Res Opin. 2024;40(6):1007\u201317. https:\/\/doi.org\/10.1080\/03007995.2024.2337662.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"683_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03079-z","volume":"19","author":"M Esgi","year":"2024","unstructured":"Esgi M, Ergun H, Kaya NY, Atakay DY, Erucar E, Celik F. Phenylketonuria from the perspectives of patients in T\u00fcrkiye. Orphanet J Rare Dis. 2024;19(1):78. https:\/\/doi.org\/10.1186\/s13023-024-03079-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"683_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-04186-1","volume":"21","author":"A Albers","year":"2026","unstructured":"Albers A, Kuni\u00df N, Kloos C, Wolf G, Schmidt S, M\u00fcller N. Navigating adulthood with PKU: metabolic outcomes, quality of life, and mental health 4.5 years post-transition. Orphanet J Rare Dis. 2026;21(1):28. https:\/\/doi.org\/10.1186\/s13023-025-04186-1.","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"683_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/nu17213409","volume":"17","author":"A Pinto","year":"2025","unstructured":"Pinto A, Daly A, Evans S, Ashmore C, MacDonald A. Navigating adolescence with PKU: adherence, metabolic control, and wellbeing in a UK clinical centre. Nutrients. 2025;17(21):3409. https:\/\/doi.org\/10.3390\/nu17213409.","journal-title":"Nutrients"},{"key":"683_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2024.101154","volume":"41","author":"A Selamio\u011flu","year":"2024","unstructured":"Selamio\u011flu A, Tando\u011fan Z, Balc\u0131 MC, Karaca M, Kozano\u011flu T, Yesil A, et al. The relationship between menstrual cycle characteristics, premenstrual syndrome prevalence and blood phenylalanine level in women with PKU. Mol Genet Metab Rep. 2024;41:101154. https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101154.","journal-title":"Mol Genet Metab Rep."},{"issue":"1","key":"683_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03824-y","volume":"20","author":"M Xue","year":"2025","unstructured":"Xue M, Shen M, Wang S, Pang B, Zhang X, Chen K, et al. Factors associated with psycho-behavioral problems among 100 children with phenylketonuria aged 6\u201318 years. Orphanet J Rare Dis. 2025;20(1):297. https:\/\/doi.org\/10.1186\/s13023-025-03824-y.","journal-title":"Orphanet J Rare Dis"},{"key":"683_CR98","doi-asserted-by":"publisher","unstructured":"Al-Hmaid Y, Alkhalili M, Faous N, Al Qa\u2019qa\u2019 S, Battah K, Marji R, et al. Quality of life in Jordanian adolescents living with PKU, a single-center, cross-sectional, observational study. J Pediatr Nurs. 2025 Nov;85:157\u201362. https:\/\/doi.org\/10.1016\/j.pedn.2025.07.027","DOI":"10.1016\/j.pedn.2025.07.027"},{"issue":"25","key":"683_CR99","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038678","volume":"103","author":"D Demirel","year":"2024","unstructured":"Demirel D, Sivri S. The struggle that is phenylketonuria: what do the patients and caregivers suffer from. Medicine (Baltimore). 2024;103(25):e38678. https:\/\/doi.org\/10.1097\/MD.0000000000038678.","journal-title":"Medicine (Baltimore)"},{"key":"683_CR100","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.ymgme.2013.10.011","volume":"110","author":"R Jahja","year":"2013","unstructured":"Jahja R, Huijbregts SCJ, De Sonneville LMJ, Van Der Meere JJ, Bosch AM, Hollak CEM, et al. Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study. Mol Genet Metab. 2013;110:S57-61. https:\/\/doi.org\/10.1016\/j.ymgme.2013.10.011.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"683_CR101","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1067\/mpd.2002.123663","volume":"140","author":"MA Landolt","year":"2002","unstructured":"Landolt MA, Nuoffer JM, Steinmann B, Superti-Furga A. Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J Pediatr. 2002;140(5):516\u201321. https:\/\/doi.org\/10.1067\/mpd.2002.123663.","journal-title":"J Pediatr"},{"issue":"2","key":"683_CR102","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/13803395.2019.1696753","volume":"42","author":"L Palermo","year":"2020","unstructured":"Palermo L, MacDonald A, Limback E, Robertson L, Howe S, Geberhiwot T, et al. Emotional health in early-treated adults with phenylketonuria (PKU): relationship with cognitive abilities and blood phenylalanine. J Clin Exp Neuropsychol. 2020;42(2):142\u201359. https:\/\/doi.org\/10.1080\/13803395.2019.1696753.","journal-title":"J Clin Exp Neuropsychol"},{"issue":"2","key":"683_CR103","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20176709","volume":"51","author":"E Vieira Neto","year":"2018","unstructured":"Vieira Neto E, Maia Filho HS, Monteiro CB, Carvalho LM, Tonon T, Vanz AP, et al. Quality of life and adherence to treatment in early-treated Brazilian phenylketonuria pediatric patients. Braz J Med Biol Res. 2018;51(2):e6709. https:\/\/doi.org\/10.1590\/1414-431x20176709.","journal-title":"Braz J Med Biol Res"},{"issue":"5","key":"683_CR104","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00431-026-06933-3","volume":"185","author":"IS Abuelela","year":"2026","unstructured":"Abuelela IS, Bebars GM, Kamal AM, Sayed SI, Refaat RS. Impact of depression on quality of life in PKU children. Eur J Pediatr. 2026;185(5):293. https:\/\/doi.org\/10.1007\/s00431-026-06933-3.","journal-title":"Eur J Pediatr"},{"key":"683_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2024.101160","volume":"41","author":"L Thomas","year":"2024","unstructured":"Thomas L, Aitkenhead L, Stepien KM, Woodall A, Macdonald A, Romani C. Cognition and wellbeing in middle-aged early treated people with phenylketonuria: preliminary results and methodological lessons. Mol Genet Metab Rep. 2024;41:101160. https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101160.","journal-title":"Mol Genet Metab Rep."},{"issue":"5","key":"683_CR106","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10545-012-9566-y","volume":"36","author":"E Thimm","year":"2013","unstructured":"Thimm E, Schmidt LE, Heldt K, Spiekerkoetter U. Health-related quality of life in children and adolescents with phenylketonuria: unimpaired HRQoL in patients but feared school failure in parents. J Inher Metab Disea. 2013;36(5):767\u201372. https:\/\/doi.org\/10.1007\/s10545-012-9566-y.","journal-title":"J Inher Metab Disea."},{"issue":"7","key":"683_CR107","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1515\/jpem-2020-0035","volume":"33","author":"R Ben Abdelaziz","year":"2020","unstructured":"Ben Abdelaziz R, Ben Chehida A, Kachouri H, Ben Messaoud S, Ferchichi M, Ben Ameur Z, et al. Quality of life and associated factors in parents of children with late diagnosed phenylketonuria. A cross sectional study in a developing country (Tunisia). J Pediatr Endocrinol Metab. 2020;33(7):901\u201313. https:\/\/doi.org\/10.1515\/jpem-2020-0035.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"683_CR108","doi-asserted-by":"publisher","first-page":"331","DOI":"10.26719\/emhj.19.045","volume":"26","author":"K Etemad","year":"2020","unstructured":"Etemad K, Heidari A, Setoodeh A, Shayeganrad A, Akhlaghi A, Azizi M, et al. Health-related quality of life of parents of children with phenylketonuria in Tehran Province, Islamic Republic of Iran. East Mediterr Health J. 2020;26(3):331\u20139. https:\/\/doi.org\/10.26719\/emhj.19.045.","journal-title":"East Mediterr Health J"},{"issue":"3","key":"683_CR109","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1515\/jpem-2018-0525","volume":"32","author":"K Iakovou","year":"2019","unstructured":"Iakovou K, Madoglou A, Monopolis I, Schulpis K. The effect of PKU diet on the maternal quality of life and social discrimination in relation to their educational status and place of living. J Pediatr Endocrinol Metab. 2019;32(3):281\u20135. https:\/\/doi.org\/10.1515\/jpem-2018-0525.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2\u20133","key":"683_CR110","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/jcap.12207","volume":"31","author":"F Irannejad","year":"2018","unstructured":"Irannejad F, Dehghan M, Mehdipour Rabori R. Stress and quality of life in parents of children with phenylketonuria. Child Adolesc Psychiatr Nurs. 2018;31(2\u20133):48\u201352. https:\/\/doi.org\/10.1111\/jcap.12207.","journal-title":"Child Adolesc Psychiatr Nurs"},{"issue":"1","key":"683_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-54","volume":"11","author":"A Fidika","year":"2013","unstructured":"Fidika A, Salewski C, Goldbeck L. Quality of life among parents of children with phenylketonuria (PKU). Health Qual Life Outcomes. 2013;11(1):54. https:\/\/doi.org\/10.1186\/1477-7525-11-54.","journal-title":"Health Qual Life Outcomes"},{"key":"683_CR112","unstructured":"Mahmoudi-Gharaei J, Mostafavi S, Alirezaei N. Quality of life and the associated psychological factors in caregivers of children with PKU. Iran J Psychiatry. 2011;6(2):66\u20139. PubMed PMID: 22952524; PubMed Central PMCID: PMC3395945."},{"issue":"1","key":"683_CR113","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1515\/jpem-2019-0384","volume":"33","author":"KK Iakovou","year":"2020","unstructured":"Iakovou KK, Schulpis K. The beneficial effect of psychological support on mothers with PKU children who suffer from social discrimination and damage of quality of life. J Pediatr Endocrinol Metab. 2020;33(1):95\u20138. https:\/\/doi.org\/10.1515\/jpem-2019-0384.","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00683-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00683-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00683-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:21:32Z","timestamp":1795018892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00683-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":113,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00683-6","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SP and VS are employees of Moderna, Inc, and own stock\/options in Moderna. TZ, DM, HV, MH, KGY, and JJH are employees of Syreon Research Institute. Syreon Research Institute received funding from Moderna, Inc. to perform the research. SV is an employee of HealthEcon Consulting, Inc, and an external consultant for Moderna, Inc. SP, VS, and SV contributed to the conceptualization, methodology, supervision, and critical review of the manuscript in their scientific capacities. The sponsor had no additional influence over the collection, analysis, or interpretation of data. All authors\u2014including those affiliated with the sponsor\u2014jointly decided to submit the manuscript. The content of this paper, as well as the views and opinions expressed therein, are those of the authors and not the organizations that employ them.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript reports a systematic literature review of previously published research. No ethical approval was required for this work, as it involves analysis of published literature only; all original studies included in our review had obtained ethical clearance as per their respective institutional and national requirements. As such, our study does not involve the collection of new primary data from human participants, nor the use of unpublished data or confidential sources. All data analyzed are in the public domain through scholarly publications.","order":2,"name":"Ethics","label":"Ethical Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is based exclusively on data extracted from previously published articles that are available in the public domain. No new primary data were collected or generated for this systematic review. All data supporting the findings of this study are contained within the published literature cited in the manuscript.","order":3,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}